Barr buys incontinence product rights
Executive Summary
Barr acquires worldwide rights to Phase II oxybutynin transvaginal ring under an agreement with Schering AG. Barr has been developing the incontinence agent for Schering AG since its acquisition of Enhance Pharmaceuticals in 2002 (1"The Pink Sheet" April 1, 2002, p. 30)...
You may also be interested in...
Barr/Enhance Acquisition’s First Product Expected To Be Oxybutynin Ring
Barr's first product to market from its acquisition of Enhance Pharmaceuticals is expected to be a vaginal ring for the treatment of urinary incontinence
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.